Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Function drives 1-year decision regret in radical prostatectomy: a multicentre prospective study.

BJU international·2026

Same author

Procedure efficiency and diagnostic outcomes during the learning curve of transperineal MRI-guided prostate biopsy.

BJUI compass·2026

Same author

Trends in surgical management of hypospadias in Germany: A nationwide analysis on legislative and guideline changes.

Journal of pediatric urology·2026

Same author

Ablative radiotherapy in castration-resistant prostate cancer.

BJU international·2026

Same author

Single-cell RNA profiling of oligodendroglial lineage cells derived from iPSCs carrying Parkinson's disease-relevant LRRK2-G2019S mutation.

iScience·2026

Same author

Knowledge Gaps and Barriers to Care in Men with Postprostatectomy Incontinence: Evidence from the German ProKontinenz Trial.

European urology open science·2026

Search research articles

Related Experiment Video

Updated: Aug 27, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Metabolic changes during prostate cancer development and progression.

Alicia-Marie K Beier^1,2, Martin Puhr³, Matthias B Stope⁴

¹Department of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.

Journal of Cancer Research and Clinical Oncology

|September 23, 2022

Summary

Prostate cancer (PCa) cells reprogram metabolism for growth, shifting from citrate use in early stages to altered pathways in advanced disease. Understanding these metabolic changes, particularly glutamine

Keywords:

CRPC Glutamine Metabolic reprogramming

More Related Videos

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging

Published on: December 30, 2016

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Related Experiment Videos

Last Updated: Aug 27, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging

Published on: December 30, 2016

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Area of Science:

Oncology
Metabolic pathways
Cancer cell biology

Background:

Metabolic reprogramming is a key hallmark of solid tumors, providing energy for growth and progression.
In prostate cancer (PCa), metabolic alterations are influenced by the androgen receptor, crucial for PCa development and survival.
Normal prostate cells utilize glycolysis for citrate secretion, unlike other epithelial cells.

Purpose of the Study:

To review the metabolic differences in prostate cancer during tumorigenesis and progression.
To highlight the role of glutamine in prostate cancer metabolism.
To explore potential therapeutic strategies targeting altered cancer metabolism.

Main Methods:

Literature review focusing on metabolic reprogramming in prostate cancer.
Analysis of metabolic shifts from normal prostate epithelium to early and advanced PCa.
Emphasis on the role of specific metabolites like citrate and glutamine.

Main Results:

Early PCa utilizes citrate for oxidative phosphorylation and lipogenesis, supporting tumor growth.
Advanced, castration-resistant PCa exhibits a metabolic shift towards choline, amino acid, and glycolytic pathways.
Glutamine plays a significant role in prostate cancer progression.

Conclusions:

Altered metabolism in prostate cancer, especially in advanced stages, offers potential therapeutic targets.
Understanding the specific metabolic reprogramming in PCa is crucial for developing novel treatment strategies.
Further research into PCa's metabolic landscape, including glutamine's role, is warranted.